De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

United Laboratories International Holdings Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	13.9yrs

Recente managementupdates

Recent updates

CEO

United Laboratories International Holdings heeft geen CEO, of we hebben geen gegevens over hen.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Hoi Shan Tsoi	Executive Chairman	15.5yrs	CN¥4.20m	0.90% HK$ 174.5m
Wing Hon Leung	Vice Chairman	17.9yrs	CN¥4.17m	0.0012% HK$ 235.3k
Su Yan Zhu	VP & Executive Director	13.9yrs	CN¥2.52m	0.000010% HK$ 1.9k
Xian Hong Zou	VP & Executive Director	13.9yrs	CN¥2.52m	0.011% HK$ 2.1m
Siu Chit Choy	Global Director of Intermediate & Bulk Medicine and Executive Director	11.3yrs	CN¥2.80m	0.0065% HK$ 1.3m
Yu Ping Fang	VP & Executive Director	13.9yrs	CN¥2.55m	geen gegevens
Ming Song	Independent Non-Executive Director	17.4yrs	CN¥234.00k	geen gegevens
Peng Oon Chong	Independent Non-Executive Director	15.6yrs	CN¥234.00k	geen gegevens
Qiushi Fu	Independent Non-Executive Director	1.3yrs	CN¥118.00k	geen gegevens

13.9yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 3933 zijn ervaren en ervaren (gemiddelde ambtstermijn van 13.9 jaar).

United Laboratories International Holdings Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

Less than half of directors are independent

Recent updates

The United Laboratories International Holdings Limited Announces the Application for Marketing of Insulin Degludec Injection

First half 2024 earnings released: EPS: CN¥0.82 (vs CN¥0.71 in 1H 2023)

The United Laboratories International Holdings Limited Declares Interim Dividend for the Six Months Ended 30 June 2024

The United Laboratories International Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 16%

The United Laboratories International Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection

the United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023

Investor sentiment deteriorates as stock falls 17%

The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection

First half 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.34 in 1H 2022)

the United Laboratories International Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for Six Months Ended 30 June 2023

New major risk - Revenue and earnings growth

The United Laboratories International Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023

Investor sentiment improves as stock rises 17%

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2022

Full year 2022 earnings released: EPS: CN¥0.87 (vs CN¥0.54 in FY 2021)

Less than half of directors are independent

CEO

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd